Kornimate/medical-research-clean huggingface dataset:
comparison of bismuth containing quadruple therapy and based tailored therapy for h. pylori infection

Conditions: Helicobacter Pylori Infection; Compliance, Patient; Drug Resistance; Antibiotics

Summary: as the antibiotic resistance increases, the eradication rate of triple therapy is decreasing. recent guideline recommend the use of bismuth-containing quadruple therapy in areas where clarithromycin resistance is greater than 15%. however, the ideal treatment would be the tailored therapy which choose the antibiotics depending on the antibiotic resistance. this study compared the eradication rates, safety and complicance of tailored therapy compared with empirical bismuth quadruple therapy in the naive patients with h. pylori infection.

in order to be eligible for first-line h. pylori eradication therapy, at least 80% of eradication rate should be achieved by intention to treat (itt) analysis. however, the triple therapy (ppi, clarithromycin, amoxicillin) is losing 1st-line therapy because of increasing antibiotic resistance. the most common cause of failure in triple therapy is clarithromycin resistance. in the past, clarithromycin resistance was rarely observed in korea, but the resistance rate has increased rapidly during the last 10 years, up to 37.3%. as an alternative, korean guidelines of helicobacter pylori eradication in 2013 recommend that bismuth-containing antibiotics (not containing clarithromycin) should be considered in areas with high clarithromycin resistance as in korea. however, there is a lack of research on the efficacy of bismuth-containing quadruple therapy as a 1st-line therapy. the aim of this prospectivce randomized study is to investingate the efficacy, conpliance, adverse events and cost-effectiveness between bismuth containing quadruple therapy and tailored therapy in areas with high clarithromycin resistance

Eligibility criteria:
inclusion criteria: * participants with peptic ulcer, s/p esd due to early gastric cancer/gastric adenoma, maltoma * ability and willingness to participate in the study and to sign and give informed consent * confirmed h. pylori infection exclusion criteria: * previous h. pylori eradication therapy * less than 18 years old * with history of h. pylori infection treatment * with previous gastric surgery * major systemic diseases * pregnancy or lactation * allergy to any of the study drugs * administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
vitamin d as treatment for chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this project aims to explore the relationship between vitamin d deficiency and copd progression via a prospective randomized placebo-controlled study. for this purpose, study was powered to 120 patients hospitalized with an exacerbation of copd randomly assigned to a monthly oral dose of vitamin d versus placebo. taking into account dropouts, 182 patients are randomized during the course of the study

principal objective: to define the therapeutic effect of vitamin d in the chronic maintenance treatment of copd by means of a prospective randomized placebo-controlled double blind study of 182 patients with a follow-up of at least one year. primary endpoint is the median time to next exacerbation. secondary endpoints are total number of exacerbations per group, number of exacerbations per patient per year, percentage of patients with one or more exacerbations per year, days of antibiotics and oral steroids, quality of life, fev1, muscle force and survival. other objectives: first, to investigate the role of local and systemic levels of 25-ohd and 1,25-(oh)2d on the intensity and prevalence of bacterial colonisation, inflammatory markers, proteases and markers of oxidative stress in induced sputa and exhaled air. second, to explore whether correction of vitamin d deficiency by the oral supplementation of vitamin d triggers the vdr-mediated cathelicidin pathway and increases local or systemic concentrations of the natural antimicrobial polypeptide cathelicidin with enhanced eradication of bacteria.

Eligibility criteria:
inclusion criteria: * primary diagnosis of copd exacerbation * smoking history of at least ten pack years * gold stage ii, iii and iv as assessed by a post-bronchodilator spirometry * informed consent exclusion criteria: * tiffeneau index \>70% or fev1 \>80% * hypercalcemia * sarcoidosis * newly discovered symptomatic osteoporosis (proven by dexa and rx ) * active cancer

Keywords: copd
hypercapnic spontaneous hyperpnoea and recovery from sevoflurane anesthesia

Conditions: Anesthesia; Surgery

Summary: the rate of elimination of inhalation agent is directly proportional to the degree of alveolar ventilation. using isocapnic hyperpnoea (ih) device, it is possible to maintain constant end-tidal co2 with increased minute ventilation. this is achieved by passively adding a flow of co2 to the inspirate in proportion to increases in ventilation above the baseline. in animal and human studies ih shortens the time of awakening from isoflurane and sevoflurane anesthesia when manual positive pressure ventilation is applied. ih device could be used for spontaneous hyperpnoea as well. the investigators want to compare recovery times from sevoflurane anesthesia in patients with application of hypercapnic spontaneous hyperpnoea (hsh) versus the standard anesthesia protocol (controls). 44 patients ill be randomized to either hsh facilitated recovery, or conventional recovery (controls).the time intervals from the end of anesthesia (turning off the vaporizer) until recovery milestones will be recorded.


Eligibility criteria:
inclusion criteria: * elective gynecological surgery * age 18-80 * asa i-iii * informed consent exclusion criteria: * asa iv-v, * contra-indications to sevoflurane anesthesia or other anesthetics included in the protocol * history of cardiac or respiratory disease * intracranial pathology * alcohol or drug abuse * psychiatric illness and/or medications

Keywords: isocapnic hyperpnoea (ih) anesthesia accelerate elimination of inhalation agents recovery from anesthesia
a phase ii trial of limited surgery and proton therapy for craniopharyngioma or observation after radical resection

Conditions: Craniopharyngioma

Summary: the goal of this study is to determine the feasibility and safety of treating patients with a brain tumor known as craniopharyngioma with limited surgery and a 5mm clinical target volume margin in combination with proton therapy. proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). irradiated patients will undergo a series of evaluations designed to evaluate the effects of proton therapy. similar evaluations will be performed on patients treated with radical surgery. proton therapy will include 30 treatment fractions administered 5 days per week. weekly imaging will be a requirement to monitor for cyst expansion and target volume deformation.

the primary objectives of this study : to estimate the progression-free and overall survival distributions for children and young adults with craniopharyngioma treated with limited surgery and proton therapy using a 5mm clinical target volume margin while monitoring for excessive central nervous system necrosis. the secondary objectives of this study: * to estimate the cumulative incidence of cystic intervention and the event-free survival distribution for children and young adults with craniopharyngioma treated with limited surgery and proton therapy using a 5mm clinical target volume margin; and compare the distributions of progression-free, event-free and overall survival with the distributions for the st. jude children's research hospital cohort of 93 patients on which the design of this trial is based. * to estimate the distributions of progression-free survival and overall survival for children and young adults with craniopharyngioma treated only with primary surgical resection and to compare these distributions with the distributions observed for patients treated with limited surgery and proton therapy.

Eligibility criteria:
inclusion criteria: * craniopharyngioma diagnosed by histology, cytology or neuroimaging. * patients ages 0-21 years at the time of diagnosis. exclusion criteria * prior history of fractionated radiation therapy. * prior treatment with intracystic p-32, intracystic bleomycin or radiosurgery. * pregnant females are excluded. radiation has teratogenic or abortifacient effects.

Keywords: proton therapy radical resection
the effect of oral guaifenesin on pediatric chronic rhinitis: a pilot study

Conditions: Chronic Rhinitis

Summary: this is a 14-day, randomized, placebo-controlled, parallel group, masked clinical trial of oral guaifenesin for the therapy of chronic rhinitis (crs) in 36 children between the ages of 7 and 18 years. the study investigates the effectiveness of guaifenesin in the relief of nasal symptoms in children with crs using the sinonasal 5 survey (sn-5) in comparison to nasal airway volume, and biophysical properties of nasal secretion. the investigators hypothesize that guaifenesin use over a period of 14 days improves subjective nasal complaints in pediatric patients with chronic rhinitis and nasal congestion, as measured by the sn-5 survey compared to use of placebo. there will be an observed improvement in nasal volume and cross-sectional area following use of guaifenesin, and nasal secretions will have more favorable mucociliary and sneeze clearability compared to use of placebo.


Eligibility criteria:
inclusion criteria: * children between the ages of 7 and 18 years, diagnosed with chronic rhinitis and nasal stuffiness for at least 3 month duration. exclusion criteria: * children with immunodeficiency, cystic fibrosis, acute or subacute symptoms, signs of bacterial infection, and/or those who are unable to cooperate with testing will be excluded. children with documented use of the study medication in the month before evaluation and during period of symptoms will also be excluded.
evaluation of outcomes of discectomy with dynesys in treatment of lumbar disc herniation

Conditions: Orthopedic Disorder of Spine

Summary: to explore the clinical outcomes of discectomy with dynamic neutralization system(dynesys) on treatment of single-segmental lumbar disc herniation(ldh) versus simple discectomy.

the study was to explore the clinical outcomes of discectomy with dynamic neutralization system(dynesys) on treatment of single-segmental lumbar disc herniation(ldh) versus simple discectomy. 128 patients with single-segmental ldh were randomly divided into discectomy with dynesys group(group a) and simple discectomy group(group b). both groups were evaluated by visual analogue score(vas), oswestry disability index(odi), radiological evidence of intervertebral height and range of motion(rom) of the treated segment at pre- and post-operation. operation duration and blood loss was recorded. the clinical outcomes and complications were evaluated afterwards. all patients received a 2-year follow-up.

Eligibility criteria:
inclusion criteria: inclusion criteria was single-segmental ldh with low back pain and radicular pain. exclusion criteria: exclusion criterias were lumbar stenosis(lss), lumbar spondylolysis and degenerative spondylolisthesis, spinal deformity, lumbar surgery history, obviously osteoporosis, vertebral fracture, cauda equina syndrome, ankylosing spondylitis, tuberculosis, infection, tumor, obesity.
kidney alone versus islet-after-kidney in type 1 diabetic kidney transplant recipient.

Conditions: type1diabetes; Renal Failure; End Stage Renal Disease

Summary: islet transplantation is associated with a benefit on glycaemic control compared to optimized insulin therapy in recent clinical trials. however, there is a lack of evidence concerning the long-term impact of islet transplantation on type 1 diabetic kidney transplant recipients' prognosis. the objective of the study is to assess the impact of islet transplantation in patients with type 1 diabetes and a kidney transplantation on the risk of graft failure. every type 1 diabetic recipient transplanted with a kidney in france between 2000 and 2017 is included. patients transplanted with pancreatic islets are compared to controls treated with insulin alone according to a matching method based on time-dependent propensity scores which allow to ensure patients comparability at the time of islet transplantation. time-dependent propensity scores are built according to variables associated with both the probabilities of being transplanted with islets and the outcome of interest. these variables are assessed by a direct acyclic graph. the primary outcome consists in death-uncensored graft survival, defined by death or return to dialysis. secondary outcomes include the risk of death, or the risk of death-censored graft survival.


Eligibility criteria:
inclusion criteria: * patient is aged over 18 * with type 1 diabetes * with end-stage renal disease * transplanted with a kidney * between 2000 and 2017 exclusion criteria: * patients with type 2 diabetes * patients with a previous pancreatic transplantation with a pancreatic graft functioning at the time of kidney transplantation.

Keywords: type 1 diabetes pancreatic islet transplantation kidney transplantation
closure of the appendix stump in laparoscopic appendectomy

Conditions: Appendicitis, Surgery

Summary: aimed to the study evaluate the superiority of intracorporal sutures and hem-o-lok clips in terms of efficiency.

performed laparoscopic surgery for acute appendicitis. appendiceal stump was closed by hem-o-lok clips (group i) and intracorporal knotting (group ii) in a randomize manner. groups were compared for cost effectiveness.

Eligibility criteria:
inclusion criteria: * diagnosis of acute appendicitis exclusion criteria: * under 18 years of age * other patology in addition to appendiceal pathology

Keywords: appendicitis; laparoscopic surgery; cost effectiveness
targeting drug memories with methylphenidate

Conditions: Substance Use Disorder; Cocaine Use Disorder

Summary: this study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. in this fmri study with a within-subjects placebo-controlled double-blind cross-over design, oral methylphenidate (20 mg) or placebo will be administered to individuals with cocaine use disorders (cud) to peak during the retrieval of a drug-cue memory before extinction; in addition to fmri activations, skin conductance responses (scr, acquired simultaneously) will serve as the psychophysiological indicators of memory modification. assessments of interference with the return of drug-cue memories via scr and craving will be conducted the day following mri. this pharmocologically-enhanced behavioral approach to decreasing drug memories and craving in icud could ultimately be used to develop effective cue-exposure therapies for drug addiction. procedures include mri, blood draw, questionnaires and interviews, skin conductance response measures, and behavioral tasks.

cue-exposure therapy has not proven efficacious in reducing relapse in drug addiction, illuminating the need for alternative strategies. here researchers will test the neural correlates of two strategies, encompassing behavioral and pharmacological approaches, aimed to interfere with the return of drug memories in individuals with cocaine use disorders. results may pave the way towards enhancing the efficacy of cue-exposure therapy in reducing cue-induced craving and relapse in drug addiction (generalizable across drugs of abuse/behavioral addictions).

Eligibility criteria:
inclusion criteria: * ability to understand and give informed consent * males and females, 18-65 years of age * dsm-v diagnosis for cud or otherwise problematic cocaine use as clinically determined exclusion criteria: * dsm-5 diagnosis for schizophrenia or developmental disorder (e.g., autism) * head trauma with loss of consciousness * history of neurological disease of central origin including seizures * cardiovascular disease including high blood pressure and/or other medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, and infectious diseases including hepatitis b and c or hiv/aids * metal implants or other mr contraindications
to explore the effect of immune-induced stereotactic body radiotherapy (sbrt) on reversing immunoresistance in stage iiic/iv non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)

Summary: the goal of this clinical trial is to learn about in describe participant population. the main questions it aims to answer are: the outcomes of the efficacy (orr) and safety (adverse events, including iraes, ae, saes, and laboratory indicators) of continued immunotherapy in patients with immune-resistant iiic/iv metastatic nsclc treated with immune-induced radiotherapy (sbrt). participants will be asked to accept the treatment of icis regimen and sbrt plan as follows: icis regimen: tislelizumab 200mg every 3 weeks, the first dose was given 7 days after the last sbrt treatment, then the first day of each cycle, 21 days as a cycle until disease progression. sbrt plan: the radiation dose and fractionation of sbrt should be evaluated according to the size and location of the tumor.


Eligibility criteria:
inclusion criteria: 1. patients with iiic/iv nsclc confirmed by histology and imaging 2. previous treatment with anti-pd1 or anti-pdl1, and resistantance to icis 3. without standard treatment regimen 4. at least one measurable target (primary tumour or metastasis) according to recist v1.1 5. age ≥ 18 and ≤ 75 6. ecog ps ≤ 2 7. life expectancy ≥ 3 months exclusion criteria: 1. autoimmune disease that might be aggravated during treatment with an immuno-stimulating agent (patients with type i diabetes, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible) 2. immunosuppressive long-term treatment (patients necessitating a corticotherapy are eligible if they are administered in doses \< or = to the equivalent of 10 mg of prednisone daily, administration of steroids by a route resulting in minimal systemic exposure (local, intra-anal, intraocular or inhalation) are eligible). 3. transplant patients (including stem cell transplants), hiv positive or other immune deficiency syndromes 4. active infection by hbv or hcv known severe hypersensitivity to monoclonal antibodies or history of anaphylactic shock, or uncontrolled asthma 5. patient with interstitial pneumonitis or pulmonary fibrosis or any other known severe respiratory insufficiency 6. patient already included in another clinical trial during treatment with an experimental
iaea-hypox. accelerated radiotherapy with or without nimorazole in squamous cell carcinoma of the head and neck

Conditions: Head and Neck Carcinoma

Summary: the purpose of this study is to test the hypothesis that radiotherapy of head and neck carcinoma can be improved by hypoxic modification of radiotherapy using nimorazole as a hypoxic radiosensitizer in association with accelerated fractionation, in an unselected patient population in a global environment.

squamous cell carcinoma in the head \& neck region (hnscc) accounts for approximately 7% of all cancers worldwide \& around 75% of all hnscc cases are seen in the less developed countries. significant improvement in loco-regional control \& disease specific survival by radiation therapy could be achieved by reducing the overall treatment time by "accelerated fractionation" schedule. modification of hypoxia by nimorazole demonstrated significant improved local effect of radiation with neither serious nor lasting side effects. so, it is expected that the optimal treatment option is reducing the overall treatment time with concomitant use of nimorazole. such treatment principle is optimal for testing in developing countries. the aim of the study: * to determine the possible therapeutic gain of using nimorazole given as a hypoxic radiosensitizer in conjunction with accelerated fractionated radiotherapy of invasive squamous cell carcinoma of the larynx, pharynx and oral cavity, and * to determine whether the addition of nimorazole to primary curative radiotherapy is feasible and tolerable on a worldwide scale. * to evaluate the tolerance, compliance and toxicity of using nimorazole.

Eligibility criteria:
inclusion criteria: * tumor classified as stage i-iv located in oropharynx, hypopharynx, larynx (not glottic stage i-ii), or oral cavity according to the tnm classification. * histopathological diagnosis of invasive squamous cell carcinoma in the primary tumor. * informed consent according to the helsinki declaration and local regula-tions. * the patient must be candidate for external beam radical radiotherapy, and must be expected to accomplish the treatment. * performance status 0-2 according to who criteria. * the patient should not have symptoms of peripheral neuropathy assessed by clinical examination. * normal function of liver and kidney by routine laboratory examinations. the patient must not be pregnant exclusion criteria: * distant metastases. * the patient should not be in a state or condition that could be expected to influence the outcome of treatment, or complicate the assessment or the treatment follow-up, or (apart from the present disease) reduce the life expectancy. * surgical excision (except biopsy), prior or planned (including elective neck dissection). * the existence of synchronous multiple malignancies (not leukoplakia).

Keywords: head and neck carcinoma accelerated radiotherapy hypoxic modification with nimorazole
neuropathic spinal pain descriptors in ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the investigators have aimed to explore and interpret the neuropathic pain (np) descriptors of spinal pain in patients with ankylosing spondylitis (as). for this purpose they have attempted to initiate a prospective, cross-sectional study with as patients.

np descriptors have been investigated in several pain syndromes such as post-herpetic neuralgia, post-surgical nerve trauma, peripheral diabetic neuropathy and low back pain. but there is no study examining descriptors of inflammatory spinal pain with or without neuropathic characteristics seen in as. to date, only one study reported distribution of sensory descriptors in neuropathic and non-neuropathic pain (nonnp) in as patients, but in this paper the painful region was not specified and the results related to sensory descriptors were not discussed. therefore, investigators have aimed to explore and interpret the sensory descriptors of inflammatory spinal pain in patients with as. for this purpose investigators have attempted to initiate a study investigating whether sensory descriptors in neuropathic pain (np) are differ from those seen in non-neuropathic pain (nonnp). the aims of this study are; 1. to determine np descriptors that associated with spinal pain in ankylosing spondylitis patients 2. to compare the patients with and without np with respect to sensory descriptors 3. to evaluate the relation between neuropathic pain (np) descriptors and functional status

Eligibility criteria:
inclusion criteria: * being diagnosed with as according to the modified newyork criteria * visual analogue scale spinal pain score ≥ 3 exclusion criteria: 1. diabetes mellitus, renal insufficiency, hypothyroidism 2. postherpetic neuralgia, spinal cord compression 3. being diagnosed as fibromyalgia in the last month or widespread pain indicating fibromyalgia 4. malignancy 5. pregnancy 6. severe cardiac disease 7. in the last three months medical treatment leading to neuropathy (colchicine etc.) 8. in the last three months drug use for the treatment of fibromyalgia, depression or anxiety